Cyclerion Therapeutics (CYCN) / Korsana Biosciences - Merger + $380M PIPE

CYCN Price: $1.55 (3/31/26 close) | Pre-market: $4.56 (+194%)Market Cap: ~$6M (pre-deal)Post-Merger: Trades as KRSA on NasdaqPIPE: ~$380M (oversubscribed)

The Deal

Cyclerion and Korsana Biosciences announced a definitive all-stock merger agreement. Combined company will operate as Korsana Biosciences under ticker KRSA. Concurrent $380M PIPE closes immediately before the merger. Cash at close funds operations into 2029.

Cyclerion is a clinical-stage company with CYC-126, an anesthetic-based therapy for treatment-resistant depression using EEG-guided closed-loop delivery. Received positive pre-IND feedback from FDA in February 2026, Phase 2 POC study planned for H2 2026 starting in Australia, with U.S. enrollment expected H1 2027. Strategic collaboration with Medsteer on the delivery platform. Small but active, not a dead listing.

The Syndicate

PIPE led by Fairmount and Venrock Healthcare Capital Partners, with General Atlantic, TCGX, Forbion, Wellington Management, Commodore Capital, RA Capital, RTW Investments, Vivo Capital, Janus Henderson, Foresite Capital, JP Morgan Life Sciences, SR One, Sanofi Ventures, Kalehua Capital, and Spruce Street Capital. Oversubscribed.

Sanofi Ventures is the strategic signal. Sanofi has neuroscience ambitions. Putting money into a preclinical Alzheimer's play at this stage is pipeline scouting, not just a financial bet.

The Science

KRSA-028 is a next-generation shuttled monoclonal antibody targeting amyloid beta for Alzheimer's disease. Built on THETA, a proprietary TfR1-based brain shuttle platform. Current approved anti-amyloid antibodies (Leqembi, Kisunla) struggle with poor brain penetration and ARIA safety risk. KRSA-028 is engineered to cross the blood-brain barrier via transferrin receptor binding, clear plaques faster, reduce ARIA, and potentially enable subcutaneous at-home dosing.

Roche (trontinemab) and AbbVie are running competing brain shuttle programs. Korsana claims preclinical data support best-in-class profile.

The Timeline

Phase 1 healthy volunteer data mid-2027. Interim proof of concept measuring amyloid plaque clearance in Alzheimer's patients end of 2027. Cash runway through 2029 covers both.

The People

CEO Jonathan Violin co-founded Quellis Biosciences (acquired by Catabasis 2021), founded Viridian Therapeutics, and co-founded Dianthus Therapeutics. Seventh company from the Paragon Therapeutics platform. Serial biotech builder with exits.

Why It Matters

Alzheimer's anti-amyloid is one of the hottest acquisition verticals in pharma. Lilly, Roche, Biogen/Eisai are all in. Lilly just dropped $6.3B on Centessa two days ago, they're buying aggressively. A best-in-class next-gen shuttle antibody with clean Phase 1 data becomes a takeout candidate immediately. The $380M war chest, elite syndicate, serial founder, and Sanofi strategic money all point the same direction.

Not Scoring Yet

KRSA doesn't trade yet. Once the merger closes, ticker changes, and Phase 1 data reads out mid-2027, dual scoring makes sense. Watchlist add for now.